missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ IL-5 Monoclonal Antibody (C1), Invitrogen™
Beschreibung
IL-5 is a cytokine that acts as a growth and differentiation factor for both B cells and eosinophils. IL-5 cytokine is a main regulator of eosinopoiesis, eosinophil maturation and activation. The elevated production of this cytokine is reported to be related to asthma or hypereosinophilic syndromes. The receptor of IL-5 cytokine is a heterodimer, whose beta subunit is shared with the receptors for interleukine 3 (IL3) and colony stimulating factor 2 (CSF2/GM-CSF). IL-5, together with those for interleukin 4 (IL4), interleukin 13 (IL13), and CSF2, form a cytokine gene cluster on chromosome 5. IL-5, IL4, and IL13 are found to be regulated coordinately by long-range regulatory elements spread over 120 kilobases on chromosome 5q31.
Spezifikation
Spezifikation
| Antigen | IL-5 |
| Anwendungen | Western Blot, Immunohistochemistry (Paraffin), Western Blot |
| Klassifikation | Monoclonal |
| Klon | C1 |
| Konzentration | 1 mg/mL |
| Konjugat | Unconjugated |
| Zusammensetzung | PBS with 50% glycerol and 0.05% Proclin 300; pH 7.4 |
| Gen | Il5 |
| Gen-Zugriffsnummer | P04401, P05113, Q08125 |
| Gen-Alias | B-cell differentiation factor I; B-cell growth factor II; BCGF-II; colony-stimulating factor, eosinophil; cytotoxic T-lymphocyte inducer; EDF; Eosinophil differentiation factor; IL5; IL-5; ILN; Interleukin; Interleukin 5; Interleukin 5 (colony-stimulating factor eosinophil); Interleukin 5 (colony-stimulating factor, eosinophil); Interleukin5; interleukin-5; T-cell replacing factor; TRF |
| Mehr anzeigen |
Name des Produkts
Indem Sie auf Absenden klicken, erklären Sie sich damit einverstanden, dass Fisher Scientific sich mit Ihnen in Verbindung setzen kann, um Ihr Feedback in diesem Formular zu bearbeiten. Wir werden Ihre Informationen nicht für andere Zwecke weitergeben. Alle bereitgestellten Kontaktinformationen werden in Übereinstimmung mit unserer Datenschutzrichtlinie aufbewahrt. Datenschutzrichtlinie.
Haben Sie Verbesserungsvorschläge?